Spindle cell carcinoma of the breast managed with neoadjuvant AIM: A case report | Zendy

April Choi | Zendy; Philip M. Carpenter | Zendy; Shefali Chopra | Zendy; Kristi Lara | Zendy; William W. Tseng | Zendy; Dakshesh B. Patel | Zendy; James Hu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Spindle cell carcinoma of the breast managed with neoadjuvant AIM: A case report

Author(s) -

April Choi,

Philip M. Carpenter,

Shefali Chopra,

Kristi Lara,

William W. Tseng,

Dakshesh B. Patel,

James Hu

Publication year - 2020

Publication title -

rare tumors

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.285

H-Index - 15

eISSN - 2036-3613

pISSN - 2036-3605

DOI - 10.1177/2036361320977021

Subject(s) - medicine , metaplastic carcinoma , mesna , ifosfamide , spindle cell carcinoma , oncology , breast cancer , carcinoma , breast carcinoma , pathology , cancer , chemotherapy , cisplatin

Spindle cell carcinoma (SpC), also known as metaplastic carcinoma—spindle cell type, is a subtype of metaplastic carcinoma. Metaplastic carcinomas of the breast are rare but are thought to be more aggressive than invasive ductal carcinomas. Due to their rarity, there are few randomized trials that can inform any standardized approaches to treatment. Treatment is instead extrapolated from other types of breast cancer or metaplastic carcinomas of different locations. Here we present the first known case report of a patient with spindle cell carcinoma of the breast successfully treated with a standard sarcoma neoadjuvant regimen of doxorubicin, ifosfamide, and mesna (AIM) that resulted in >99% necrosis of the tumor and negative margins at the time of resection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research